Pharmaceutical Translation: Clinical Trials, Regulatory Submissions, and Drug Labeling
The pharmaceutical industry operates globally, and accurate translation is critical at every stage — from clinical research to regulatory approval to patient-facing labeling. A single translation error in a clinical trial document could compromise patient safety, invalidate research data, or delay drug approval. Pharmaceutical translation services require the highest level of precision, domain expertise, and regulatory awareness.
Why Pharmaceutical Translation Is Different
Regulatory Stakes
Pharmaceutical translations are reviewed by regulatory agencies worldwide:
FDA (United States) — Food and Drug Administration
EMA (European Union) — European Medicines Agency
PMDA (Japan) — Pharmaceuticals and Medical Devices Agency
NMPA (China) — National Medical Products Administration
Health Canada
TGA (Australia) — Therapeutic Goods Administration
ANVISA (Brazil)
Each agency has specific language requirements for submissions, and errors can result in:
Rejection of submissions, Delays in drug approval, Clinical holds, Warning letters, and Patient safety issues
Patient Safety
Pharmaceutical translations directly affect patient safety. Mistranslated:
Dosing instructions could lead to overdose or underdose
Contraindications could result in dangerous drug interactions
Adverse event descriptions could lead to underreporting of side effects
Informed consent forms could violate patients' rights to understand risks
Legal Liability
Pharmaceutical companies face significant legal liability for translation errors:
Product liability lawsuits from patients harmed by mistranslated labeling, Regulatory penalties for non-compliant submissions, and Clinical trial liability for inadequate informed consent
Clinical Trial Translation
Informed Consent Forms (ICF)
The informed consent form is the most critical patient-facing document in a clinical trial. It explains:
The purpose of the trial, Procedures involved, Potential risks and benefits, Alternatives to participation, Rights of the participant (including the right to withdraw), Confidentiality protections, and Contact information for questions
ICH GCP (Good Clinical Practice) E6(R2) requires that informed consent be obtained in a language the participant understands. For multinational trials, the ICF must be translated into the local language of each participating site.
Translation requirements:
Clinical Trial Protocols
The trial protocol describes the study design, objectives, methodology, and statistical considerations. While protocols are typically in English for international trials, local regulatory authorities may require translated versions.
Case Report Forms (CRFs)
Electronic or paper forms used to collect patient data. If site staff need to record information in the local language, CRFs must be translated.
Investigator's Brochure (IB)
The IB compiles clinical and non-clinical data about the investigational product. While often kept in English, local regulations may require translation.
Patient Diaries and Questionnaires
Patient-reported outcome (PRO) instruments must be linguistically validated — a process more rigorous than standard translation:
This process (following ISPOR guidelines) ensures the translated instrument measures the same construct as the original.
Adverse Event Reports
Adverse events reported at non-English-speaking sites must be translated for sponsor review and regulatory reporting. These translations must be:
Rapid (serious adverse events have 24-hour reporting timelines), Accurate (medical terminology must be precise), and Complete (every detail matters for safety analysis)
Regulatory Submission Translation
FDA Submissions
The FDA requires documents to be in English. For drugs developed abroad with foreign-language source documents, translations are needed for:
Common Technical Document (CTD) modules, Clinical study reports, Non-clinical study reports, Chemistry, Manufacturing, and Controls (CMC) documentation, and Labeling
EMA Submissions
The EMA accepts submissions in English but may require translations of:
Summary of Product Characteristics (SmPC) into all EU official languages, Package leaflet into all EU official languages, and Labeling into all EU official languages for marketing authorization
Japan (PMDA)
The PMDA requires submissions in Japanese. This includes:
Application forms, CTD modules (may be translated from English), Labeling (in Japanese), and Clinical study summaries
China (NMPA)
The NMPA requires submissions in Chinese. All documentation must be translated from the source language into Simplified Chinese.
Drug Labeling and Packaging
Prescribing Information (PI) / Summary of Product Characteristics (SmPC)
The PI/SmPC is the healthcare professional-facing document that describes:
Indications and usage, Dosage and administration, Warnings and precautions, Adverse reactions, Drug interactions, Clinical pharmacology, and Clinical studies
Translation must use standardized medical terminology (MedDRA — Medical Dictionary for Regulatory Activities) and comply with local regulatory formatting requirements.
Patient Package Insert (PPI) / Package Leaflet
The patient-facing insert must be:
Translated into the local language, Written at an appropriate reading level, Culturally adapted where necessary, and Reviewed and approved by the regulatory authority
Carton and Container Labels
Product labels must include:
Drug name (brand and generic INN), Strength and dosage form, Route of administration, Warnings, Storage conditions, Lot number and expiration date, and Manufacturer information
Label translation must be exact — space constraints on physical labels require precise, concise translations.
Quality Standards in Pharmaceutical Translation
ISO 17100
The general translation quality standard requires:
Qualified translators with subject matter expertise, Revision by a second translator, Project management processes, and Quality assurance procedures
ISO 9001
Quality management system standard, often required by pharmaceutical companies for their vendors.
Back-Translation
Common in pharmaceutical translation, especially for:
Informed consent forms, Patient-reported outcomes, and Marketing claims
Back-translation involves translating the translated text back into the source language and comparing it to the original to identify discrepancies.
Terminology Management
Pharmaceutical translation requires strict terminology management:
MedDRA terms for adverse events and medical conditions
INN (International Nonproprietary Names) for drug substances
Pharmacopeial terms (USP, EP, JP) for excipients and test methods
Company-specific glossaries for proprietary terms
Common Pharmaceutical Translation Challenges
Drug Name Translation
Drug names require careful handling:
Brand names are typically not translated (they are trademarks)
INN (generic names) follow international conventions but may have language-specific forms
Chemical names follow IUPAC nomenclature but are expressed differently in different languages
Dosing Instructions
"Take one tablet twice daily" must be translated with absolute precision. Ambiguity in dosing instructions can have life-threatening consequences.
Medical Device Integration
Combination products (drug + device) require translation of:
Instructions for Use (IFU), Device labeling, Quick reference guides, and Training materials
Multilingual Packaging
Products sold in multiple countries may have multilingual packaging. Translation must be:
Consistent across all languages, Space-efficient (fitting multiple languages on small labels), and Compliant with each country's language requirements
Link Translations Pharmaceutical Services
Link Translations provides specialized translation for the pharmaceutical and life sciences industry.
Informed consent form translation and linguistic validation, Regulatory submission translation (FDA, EMA, PMDA, NMPA), Drug labeling and packaging translation, Clinical trial document translation, MedDRA-standardized terminology, ISO 17100-compliant quality processes, and Confidentiality agreements and IP protection
Contact us for a pharmaceutical translation consultation.